1 week Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 27,700 shares of the company’s stock, valued at approximately $219,000.
Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd.
acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $81,000. Cibc World Markets Corp purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth about $118,000. Janney Montgomery Scott LLC acquired a new stake in Amneal Pharmaceuticals during the fourth quarter worth about $121,000.
Quadrature Capital Ltd purchased a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $169,000. Finally, Amundi acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $256,000. Hedge funds and other institutional investors own 31.
82% of the company’s stock. Amneal Pharmaceuticals Stock PerformanceAmneal Pharmaceuticals stock opened at $7.21 on Tuesday.
The stock has a market capitalization of $2.23 billion, a P/E ratio of -10.60 and a beta of 1.
06. The company’s fifty day moving average price is $8.33 and its 200 day moving average price is $8.
33. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.
18 and a 1 year high of $9.48. Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its earnings results on Friday, February 28th.
The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.
03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.
26%. The company had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.
21 million. During the same quarter last year, the business earned $0.14 EPS.
Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.
Insiders Place Their BetsIn other news, Director Gautam Patel sold 62,590 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.
90. Following the completion of the sale, the director now directly owns 1,968,886 shares in the company, valued at $15,770,776.86.
This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.
00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15.
The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
In the last three months, insiders sold 5,222,590 shares of company stock worth $43,614,546. Corporate insiders own 26.56% of the company’s stock.
Wall Street Analysts Forecast GrowthA number of brokerages have recently commented on AMRX. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.
00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th.
Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $12.
00 in a research note on Monday, February 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.
80.View Our Latest Stock Report on Amneal PharmaceuticalsAmneal Pharmaceuticals Profile (Free Report)Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE.
The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.See AlsoFive stocks we like better than Amneal PharmaceuticalsWhat is Insider Trading? What You Can Learn from Insider TradingOptions Activity Points to More Volatility for Palantir StockBest of the list of Dividend Aristocrats: Build wealth with the aristocrat indexNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Canadian Penny Stocks: Can They Make You Rich? MicroStrategy Sees Insider Buy-Sell Action in Q1Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc.
(NASDAQ:AMRX – Free Report)..
